GLPG2222 150 mg q.d.
GLPG2222-CL-201
Phase 2 small_molecule completed
Quick answer
GLPG2222 150 mg q.d. for Cystic Fibrosis is a Phase 2 program (small_molecule) at Lakefront Biotherapeutics NV with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lakefront Biotherapeutics NV
- Indication
- Cystic Fibrosis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed